A BILL 
To authorize the Food and Drug Administration to require 
manufacturers of infant formula to warn about a dis-
continuance or interruption in the production of infant 
formula, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Formula Shortage Re-
4
porting Act of 2022’’. 
5
22:00 Jun 14, 2022
H8038
2 
•HR 8038 IH
SEC. 2. REQUIREMENT TO WARN ABOUT DISCONTINUANCE 
1
OR INTERRUPTION IN THE PRODUCTION OF 
2
INFANT FORMULA. 
3
(a) IN GENERAL.—Section 412 of the Federal Food, 
4
Drug, and Cosmetic Act (21 U.S.C. 350a) is amended by 
5
adding at the end the following: 
6
‘‘(j)(1) A manufacturer of infant formula shall notify 
7
the Secretary, in accordance with paragraph (2), of a per-
8
manent discontinuance in the manufacture of the infant 
9
formula or an interruption of the manufacture of the in-
10
fant formula that is likely to lead to a meaningful disrup-
11
tion in the supply of that infant formula in the United 
12
States, or a permanent discontinuance in the manufacture 
13
of an infant formula component or an interruption in the 
14
manufacture of an infant formula component that is likely 
15
to lead to a meaningful disruption in the supply of the 
16
infant formula component, and the reasons for such dis-
17
continuance or interruption. Notification under this sub-
18
section shall include disclosure of— 
19
‘‘(A) reasons for the discontinuance or interrup-
20
tion; 
21
‘‘(B) if an infant formula component is a rea-
22
son for, or a risk factor in, such discontinuance or 
23
interruption, the source of the infant formula com-
24
ponent and any alternative sources for the infant 
25
formula component known by the manufacturer; 
26
22:00 Jun 14, 2022
H8038
3 
•HR 8038 IH
‘‘(C) whether any associated device used for 
1
preparation or administration included in the infant 
2
formula is a reason for, or a risk factor in, such dis-
3
continuance or interruption; 
4
‘‘(D) in the case of an interruption, the ex-
5
pected duration of the interruption; and 
6
‘‘(E) such other information as the Secretary 
7
may require. 
8
‘‘(2) A notice required under paragraph (1) shall be 
9
submitted to the Secretary— 
10
‘‘(A) at least 72 hours prior to the date of the 
11
discontinuance or interruption; or 
12
‘‘(B) if compliance with subparagraph (A) is 
13
not possible, as soon as practicable. 
14
‘‘(3) If a manufacturer of infant formula determines 
15
that compliance with paragraph (2)(A) is not possible, the 
16
manufacturer shall submit such determination in writing 
17
to the Secretary and the justification for such determina-
18
tion. 
19
‘‘(4) To the maximum extent practicable, the Sec-
20
retary shall distribute to health care providers who treat 
21
pregnant women and children under the age of 2, and 
22
make publicly available on the website of the Food and 
23
Drug Administration, information on the discontinuance 
24
22:00 Jun 14, 2022
H8038
4 
•HR 8038 IH
or interruption of the manufacture of the infant formula 
1
described in paragraph (1). 
2
‘‘(5) Nothing in this subsection shall be construed as 
3
authorizing the Secretary to disclose any information that 
4
is a trade secret or confidential information subject to sec-
5
tion 552(b)(4) of title 5, United States Code, or section 
6
1905 of title 18, United States Code. 
7
‘‘(6) The Secretary shall find a manufacturer of in-
8
fant formula to be in violation of this section if— 
9
‘‘(A) the Secretary determines that— 
10
‘‘(i) the manufacturer has failed to submit 
11
the notice required by paragraph (2) and the 
12
determination and justification required by 
13
paragraph (3); or 
14
‘‘(ii) the determination and justification 
15
submitted by the manufacturer are insufficient; 
16
‘‘(B) the Secretary issues a letter to such man-
17
ufacturer— 
18
‘‘(i) informing such manufacturer of such 
19
failure or insufficiency; and 
20
‘‘(ii) giving such manufacturer a period of 
21
not more than 30 calendar days to correct such 
22
failure or insufficiency; and 
23
22:00 Jun 14, 2022
H8038
5 
•HR 8038 IH
‘‘(C) the Secretary determines such manufac-
1
turer has failed to correct such failure or insuffi-
2
ciency by the end of such period. 
3
‘‘(7) For purposes of this subsection— 
4
‘‘(A) the term ‘infant formula component’ 
5
means a raw or in-process material, ingredient, con-
6
tainer, or closure used in the manufacturing or proc-
7
essing of infant formula; 
8
‘‘(B) the term ‘infant formula shortage’ or 
9
‘shortage’, with respect to an infant formula, means 
10
a period of time when the demand or projected de-
11
mand for the infant formula within the United 
12
States exceeds the supply of the infant formula; and 
13
‘‘(C) the term ‘meaningful disruption’— 
14
‘‘(i) means a change in production that is 
15
reasonably likely to lead to a reduction in the 
16
supply of an infant formula by a manufacturer 
17
that is more than negligible and affects the 
18
ability of the manufacturer to fill orders or 
19
meet expected demand for its product; and 
20
‘‘(ii) does not include interruptions in man-
21
ufacturing due to matters such as routine main-
22
tenance or insignificant changes in manufac-
23
turing so long as the manufacturer expects to 
24
resume operations in a short period of time.’’. 
25
22:00 Jun 14, 2022
H8038
6 
•HR 8038 IH
(b) PROHIBITED ACT.—Section 301 of the Federal 
1
Food, Drug, and Cosmetic Act (21 U.S.C. 331) is amend-
2
ed by adding at the end the following: 
3
‘‘(fff) The failure by a manufacturer of infant for-
4
mula, with respect to a notice of discontinuance or inter-
5
ruption, to make a correction as required by section 
6
412(j)(6)(C).’’. 
7
Æ 
22:00 Jun 14, 2022
H8038
